Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Systemic therapy with or without entecavir in advanced hepatocellular carcinoma with chronic hepatitis B
ChiCTR-IPC-14005410Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Nov 2014
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sorafenib, entecavir, oxaliplatin and tegafur in hepatocellular carcinoma (HCC) and Chronic Hepatitis B (CHB) (3 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: Overall survival and Progression-free survival. Started Nov 2014; status: recruiting.
02
Drugs
sorafenibentecaviroxaliplatintegafur
03
Conditions
hepatocellular carcinoma (HCC)Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ChiCTR-IPC-14005410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPC-14005410.